United States & Gilead Sciences
11 shared events · Importance 7 · Last updated Jul 04, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States: The United States>>> market now has the first approved treatment for chronic hepatitis delta virus, addressing a significant public health need for an estimated 40,000 to 80,000 people.
Gilead Sciences: The approval of Hepcludex by the United States — Food and Drug Administration>>> expands Gilead Sciences>>>' liver disease portfolio and positions it as a primary player in the hepatitis D treatment market. This approval is a significant commercial advancement for Gilead Sciences>>>.
May 22, 2026 · 10 articles
International
United States: US funding cuts under President Trump drove the global decline, though the US still provides 74% of donor funding.
Gilead Sciences: Facing pressure to expand access to lenacapavir; its pricing and licensing decisions are under scrutiny.
Jul 21, 2026 · 68 articles
Accidents
United States: United States>>> has bolstered precautions, including screening air passengers and suspending visa services, and has provided $13 million in assistance for the response.
Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.
May 15, 2026 · 446 articles
Accidents
United States: Restricted direct flights from DRC; delayed minerals partnership talks; CDC involved in response.
Gilead Sciences: Developed obeldesivir, the antiviral being tested in the EBO-PEP trial.
Jul 06, 2026 · 410 articles
International
United States: United States>>> proposed establishing an Ebola quarantine facility in Kenya>>> for its citizens exposed to the virus, aiming to prevent Ebola cases from entering its territory. This policy shift has drawn criticism from public health experts and led to a court suspension in Kenya>>>.
Gilead Sciences: Gilead Sciences' antiviral remdesivir is mentioned as a potential treatment to be used at the quarantine facility, indicating its role in the medical response to Ebola.
May 26, 2026 · 213 articles
International
United States: The United States>>> has announced additional aid to the Democratic Republic of the Congo>>> for the Ebola response and has implemented temporary travel bans for non-citizens from affected countries. It also plans to establish a quarantine facility in Kenya>>> for exposed Americans.
Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.
May 21, 2026 · 627 articles
Tech
United States: Country where the study was conducted; public health implications for transplant recipients.
Gilead Sciences: Manufactures remdesivir (Veklury). Positive study results may support increased use and sales in transplant populations.
Jul 28, 2026 · 6 articles
Accidents
United States: The United States>>> has pledged financial aid and is monitoring the Ebola outbreak, with some of its citizens exposed or infected, but its previous aid cuts and withdrawal from the World Health Organization>>> have been criticized for weakening global health response capacity.
Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.
May 18, 2026 · 505 articles
Domestic
United States: The United States is the context for this political and legal event. The contempt vote reflects partisan divisions that could affect governance and public trust.
Gilead Sciences: Gilead is mentioned in relation to Remdesivir, but it is not directly involved in the event. Its role is peripheral.
Jul 26, 2026 · 353 articles
Regulatory
Gilead Sciences: Gilead Sciences is among the pharmaceutical companies that agreed to lower drug prices for United States — Medicaid and cash payers as part of the deals with the Donald Trump administration.
Dec 19, 2025 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and Gilead Sciences interact across events, view sentiment trends, and discover connected entities.
Open Dashboard